Navigation Links
Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Date:4/22/2008

HONG KONG, April 22 /PRNewswire/ -- OrbusNeich's Genous Bio-engineered R stent will be featured at a sponsored symposium during Angioplasty Summit TCT 2008 Asia Pacific.

The symposium, which will take place on April 23 at the Convention Center of Sheraton Grande Walkerhill Seoul Hotel in Seoul, Korea, includes:
-- "Opening Address" by Seung-Jung Park, the symposium's chairperson, from

12:30 p.m.-12:35 p.m.

-- "Endothelial Progenitor Cell Capture Technology and Beyond" by Michael

Kutryk from 12:35 p.m.-12:50 p.m.

-- "TRIAS HR Pilot Study Long Term Follow-up" by Robbert de Winter of the

Academic Medical Center, Amsterdam, from 12:50 p.m.-1:05 p.m.

-- "HEALING AMI" by Harry Suryapranata from 1:05 p.m.-1:20 p.m.

-- "Q&A Followed by Closing Remarks" by Seung-Jung Park from

1:20 p.m.-1:30 p.m.

"Recent data has highlighted the need for a safer alternative to drug-eluting stents," said Seung-Jung Park. "The data we have seen from both the TRIAS HR Pilot study and the registries underline Genous' superior safety profile with regards to late stage thrombosis."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com .


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 5W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation
2. Symposium to explore role nanoparticles may play in disease
3. NARSADs 5th Annual Mission Possible Symposium Offers Insight to PTSD and Other Mental Illnesses
4. Global Sound Conference Brings Worlds Top Sound Researchers, Technologists and Musicians to Los Angeles for Four Day Symposium
5. Eating Disorders Take Center Stage at iaedp(TM) 2008 Symposium in Orlando, Florida
6. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
7. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
8. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
9. AAAS symposium to address significant effects of the male parent in reproductive success
10. Symposium on drug-resistant diseases set for annual AAAS conference
11. Studies on Urgent(R) PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... Levels of a ... damage, according to a study appearing online in the journal Radiology. , Heart disease ... to increase significantly due to the rapidly aging population. Damage to both organs often ...
(Date:12/7/2016)... ... , ... They are musicians and librarians, fashion designers and fitness instructors, actors, ... England and around the nation. What do they have in common? All have been ... and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in ...
(Date:12/7/2016)... Hollywood, Fl (PRWEB) , ... December 07, 2016 , ... When it came time to ... new heart. Just 40 minutes later, the Pediatric Heart Transplant team at Joe ... true making the Weston teen the hospital’s 30th heart transplant recipient. , “He was ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... to the US market its advanced highly customizable contact technology solutions. , ODU ... These advanced technologies are ideal for a wide range of applications that require ...
(Date:12/7/2016)... Arbor, MI (PRWEB) , ... December 07, 2016 ... ... insurance and financial consultation services from offices located in South Lyon, Dewitt, Williamston, ... to benefit a basketball coach who needs treatment for a brain tumor. , ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Boehringer Ingelheim today announced that the ... malignant pleural mesothelioma (MPM) met its primary endpoint ... the 17 th IASLC World Conference on ... showed nintedanib plus pemetrexed/cisplatin demonstrated a meaningful clinical ... significantly improved PFS (9.4 vs 5.7 months). Preliminary ...
(Date:12/7/2016)... Dec. 7,2016  Based on its recent ... Frost & Sullivan recognizes Nemaura Pharma Limited ... Award for Enabling Technology Leadership. Nemaura Pharma,s ... in traditional drug delivery technologies, especially in ... drug delivery technologies, Memspatch and Micropatch respectively, ...
(Date:12/7/2016)... DIEGO , Dec. 7, 2016  Organovo ... a three-dimensional biology company focused on delivering scientific ... today announced that Chairman and Chief Executive Officer ... at VirtualInvestorConferences.com on Wednesday, December 14, 2016 at ... investors who are not yet familiar with the ...
Breaking Medicine Technology: